Skip to main content
Clinical Trials/NCT04409665
NCT04409665
Unknown
Phase 1

The Use of Sedation Drugs in the Procedure of Administering Surfactant Without Intubation (LISA/MIST): a Randomized Study Comparing Intravenous Ketamine With Sublingual 30% Glucose

Medical University of Warsaw1 site in 1 country60 target enrollmentJanuary 1, 2020

Overview

Phase
Phase 1
Intervention
Ketamine
Conditions
Neonatal Respiratory Distress Syndrome
Sponsor
Medical University of Warsaw
Enrollment
60
Locations
1
Primary Endpoint
Assessment of patient sedation
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the efficacy and impact of intravenous ketamine or sublingual 30% glucose as sedation drugs used in preterm premature babies during the LISA procedure. The second goal is to compare the frequency of complications during LISA with both premedication regimens.

Detailed Description

All infants fulfilling the inclusion criteria during the 12 months recruitment window will potentially be enrolled in this randomized controlled trial of LISA premedication. Written informed consent will be acquired from parents or legal guardians. After the consent, infants needing the LISA will receive premedication as follows: caffeine citrate according to the clinical routine at study site, and randomly, either ketamine or sublingual glucose 30%. This study is a pilot study and 60 patients that will be randomized 1:1. Ketamine will be given in slow intravenous injection over 60 seconds. Glucose 30% will be given sublingually in the volume of 1 mL. After two minutes (from the end of administration of the study drug or reference drug), laryngoscopy will be started. To assess the effectiveness of both types of sedation, patients will be assessed using two pain assessment scales - the COMFORT scale and the FANS scale. 10 minutes before the procedure, the first assessment in the COMFORT and FANS scales will take place. The next assessment on both scales will take place during the procedure.

Registry
clinicaltrials.gov
Start Date
January 1, 2020
End Date
April 30, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Medical University of Warsaw
Responsible Party
Principal Investigator
Principal Investigator

PAWEL KRAJEWSKI, MD

Head of the division of neonatology

Medical University of Warsaw

Eligibility Criteria

Inclusion Criteria

  • Infant with established Respiratory Distress Syndrome (RDS) or at risk for RDS
  • Gestational age 28 0/7 - 32 6/7 weeks
  • Non-invasive respiratory support with nasal CPAP (incl. BiPAP) or NIPPV
  • Need for administration of exogenous surfactant

Exclusion Criteria

  • Need for intubation and mechanical ventilation at the Delivery Room
  • Infant with clinically significant maxillo-facial, tracheal or pulmonary malformations

Arms & Interventions

Ketamine sedated group

30 randomized patients will receive Ketamine 1 mg/kg , I.V. 2 minutes before LISA

Intervention: Ketamine

Glucose sedated group

30 patients will receive Glucose 30% 1 mL, sublingually, 2 minutes before LISA

Intervention: Glucose

Outcomes

Primary Outcomes

Assessment of patient sedation

Time Frame: First assessment 10 minutes before procedure, second during the procedure

Assessment of patient sedation change before and after LISA using FANS scale

Comparing ketamine and glucose

Time Frame: Comparing the scores through study completion, an average of two years

Comparison of the effectiveness of sedation with ketamine and glucose using the COMFORT scale scores. The Comfort scale ranges from 8 points at minimum, to 40 at maximum. The higher the score, the lower the sedation level.

Secondary Outcomes

  • Frequency of complications(During the procedure)

Study Sites (1)

Loading locations...

Similar Trials